Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
2025 · Journal for ImmunoTherapy of Cancer · 15 citations
https://doi.org/10.1136/jitc-2024-010674